Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease (original) (raw)
Brief Articles
Copyright ©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. May 28, 2009; 15(20): 2506-2511
Published online May 28, 2009. doi: 10.3748/wjg.15.2506
Table 2 Etiology, mean age and prevalence of type 2 diabetes mellitus in 465 HCC patients (mean ± SD)
| Etiology | HCC n (%) | Age (yr) | Prevalence of DM2 (%) |
|---|---|---|---|
| HBV | 20 (4.3) | 63.3 ± 10.3a | 3 (15.0) |
| HCV | 177 (38.1) | 71.5 ± 7.3a | 47 (26.5)bc |
| Alcohol | 141 (30.4) | 66.7 ± 8.5a | 52 (36.9)bd |
| HBV + HCV | 8 (1.7) | 60.8 ± 12.8a | 2 (25.0) |
| HBV + alcohol | 9 (1.9) | 62.9 ± 9.3a | 2 (22.2) |
| HCV + alcohol | 81 (17.4) | 67.7 ± 9.3a | 27 (33.3) |
| HBV + HCV + alcohol | 2 (0.4) | 68.4 ± 10.3 | 0 |
| Cryptogenic | 27 (5.8) | 68.6 ± 9.3 | 19 (70.3)cd |
- Citation: Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506-2511
- URL: https://www.wjgnet.com/1007-9327/full/v15/i20/2506.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.2506